US Capitol Capsule: Advance Science, Don't Pressure FDA On Approvals, Drug Chief Tells Advocates

12 Oct 2015

• By Donna Young

"Patient advocacy groups should be in the business of advocating for patients, not advocating for specific drugs or development programs," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER), insisted last week at the Biotechnology Industry Organization's 2015 Patient and Health Advocacy Summit in Washington.

"I don't think it's that healthy to engage patients and advocates for a drug," Woodcock told Scrip after the meeting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

26 Mar 2025

• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

20 Mar 2025

• By Andrew McConaghie

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

Sarepta Shares Plummet On News Of Elevidys Patient Death

18 Mar 2025

• By Joseph Haas

The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

21 Feb 2025

• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.